Douglas Jermasek
Corporate Officer/Principal bei UNICYCIVE THERAPEUTICS, INC.
Vermögen: 169 762 $ am 30.04.2024
Profil
Douglas Jermasek currently works at Unicycive Therapeutics, Inc., as Executive Vice President-Corporate Strategy from 2021.
Mr. Jermasek also formerly worked at Deltanoid Pharmaceuticals, Inc., as Chief Executive Officer, Keryx Biopharmaceuticals, Inc., as Vice President-Marketing & Strategy from 2016 to 2018, Genzyme Corp., as Senior Vice President & General Manager, and Akebia Therapeutics, Inc., as Senior Vice President-Marketing & Strategy.
Mr. Jermasek received his undergraduate degree from Brigham Young University and Masters Business Admin degree from BYU Marriott School.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 15.04.2024 | 175 012 ( 0,50% ) | 169 762 $ | 30.04.2024 |
Aktive Positionen von Douglas Jermasek
| Unternehmen | Position | Beginn |
|---|---|---|
| UNICYCIVE THERAPEUTICS, INC. | Corporate Officer/Principal | 26.10.2021 |
Ehemalige bekannte Positionen von Douglas Jermasek
| Unternehmen | Position | Ende |
|---|---|---|
| KERYX BIOPHARMACEUTICALS | Vertrieb & Marketing | 12.12.2018 |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - |
| AKEBIA THERAPEUTICS, INC. | Vertrieb & Marketing | - |
Deltanoid Pharmaceuticals, Inc.
 Deltanoid Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Deltanoid Pharmaceuticals, Inc. researches and develops therapies for the treatment of human diseases. The firm's focus is to move therapies in a variety of areas, including renal disease, osteoporosis, vitamin D deficiency, and acne through the drug development process and seek partners for later stage development and commercialization. The company was founded by Margaret Clagett-Dame and Hector F. DeLuca in 1999 and is headquartered in Madison, WI. | Vorstandsvorsitzender | - |
Ausbildung von Douglas Jermasek
| BYU Marriott School | Masters Business Admin |
| Brigham Young University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| UNICYCIVE THERAPEUTICS, INC. | Health Technology |
| AKEBIA THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 3 |
|---|---|
Deltanoid Pharmaceuticals, Inc.
Deltanoid Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Deltanoid Pharmaceuticals, Inc. researches and develops therapies for the treatment of human diseases. The firm's focus is to move therapies in a variety of areas, including renal disease, osteoporosis, vitamin D deficiency, and acne through the drug development process and seek partners for later stage development and commercialization. The company was founded by Margaret Clagett-Dame and Hector F. DeLuca in 1999 and is headquartered in Madison, WI. | Commercial Services |
Keryx Biopharmaceuticals, Inc.
 Keryx Biopharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Keryx Biopharmaceuticals, Inc. engaged in the manufacture, development, and commercialization of medicines for use in treating human diseases. The company was founded in August 1, 2002 and was headquartered in Cambridge, MA. | Health Technology |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
